SML1244
Efinaconazole
≥98% (HPLC)
동의어(들):
(αR,βR)-, α-(2,4-Difluorophenyl)-β-methyl-4-methylene-α-(1H-1,2,4-triazol-1-ylmethyl)-1-piperidineethanol, (2R,3R)-2-(2,4-Difluorophenyl)-3-(4-methylenepiperidin-1-yl)-1-(1H-1,2,4-triazol-1-yl)butan-2-ol, KP-103
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C18H22F2N4O
CAS Number:
Molecular Weight:
348.39
UNSPSC 코드:
51111800
NACRES:
NA.77
추천 제품
Quality Level
분석
≥98% (HPLC)
형태
powder
광학 활성
[α]/D -85 to -95°, c = 1 in chloroform
색상
white to beige
solubility
DMSO: 20 mg/mL, clear
저장 온도
−20°C
InChI
1S/C18H22F2N4O/c1-13-5-7-23(8-6-13)14(2)18(25,10-24-12-21-11-22-24)16-4-3-15(19)9-17(16)20/h3-4,9,11-12,14,25H,1,5-8,10H2,2H3/t14-,18-/m1/s1
InChI key
NFEZZTICAUWDHU-RDTXWAMCSA-N
애플리케이션
Efinaconazole has been used as:
- a topical anti-onychomycosis drug to determine its effects on Trichophyton rubrum and Trichophyton interdigitale
- as an anti-fungal agent to study its permeability into the nail lysates
- as an anti-fungal agent to study its effects on Candida africana and Candida dubliniensis
생화학적/생리학적 작용
Efinaconazole exhibits its activity against pathogens such as Trichophyton mentagrophytes, Trichophyton rubrum, and Candida albicans. It is active against Candida sp. that cause nail and skin candidiasis. Efinaconazole is also effective against Malassezia sp. that causes tinea versicolor.
Efinaconazole is a triazole antifungal drug approved clinically for the treatment of nail fungus (Onychomycosis). It inhibits sterol biosynthesis by inhibition of cytochrome P450 14α-demethylase, an enzyme in the sterol biosynthesis pathway that leads from lanosterol to ergosterol. Efinaconazole has better nail penetration, so is more effective than other topical agents and as effective as oral medication for nail fungus.
신호어
Warning
유해 및 위험 성명서
Hazard Classifications
Repr. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
William J Jo Siu et al.
Antimicrobial agents and chemotherapy, 57(4), 1610-1616 (2013-01-16)
Onychomycosis is a common fungal nail infection in adults that is difficult to treat. The in vitro antifungal activity of efinaconazole, a novel triazole antifungal, was evaluated in recent clinical isolates of Trichophyton rubrum, Trichophyton mentagrophytes, and Candida albicans, common
Gholamreza Shokoohi et al.
Mycoses, 64(7), 771-779 (2021-04-04)
Vulvovaginal candidiasis (VVC) is a common and debilitating long-term illness affecting million women worldwide. This disease is caused mainly by Candida albicans and a lesser extent by other species, including the two phylogenetically closely related pathogens Candida africana and Candida
Keita Sugiura et al.
Journal of fungi (Basel, Switzerland), 7(3) (2021-04-04)
To evaluate the combination effects of anti-onychomycosis drugs, the minimum inhibitory concentrations of topical (efinaconazole, luliconazole, and tavaborole) and oral (itraconazole and terbinafine) drugs for Trichophyton rubrum and Trichophyton interdigitale (8 each, with a total of 16 strains) were determined
Assessment of the nail penetration of antifungal agents, with different physico-chemical properties.
Heather Davies-Strickleton et al.
PloS one, 15(2), e0229414-e0229414 (2020-02-29)
Onychomycosis, or fungal nail infection, is a common fungal infection largely caused by dermatophyte fungi, such as Trichophyton rubrum or Trichophyton mentagrophytes, which affects a significant number of people. Treatment is either through oral antifungal medicines, which are efficacious but
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.